inhibits serotonin reuptake. Compared to S-(+)-ketamine, the less potent anesthetic enantiomer R(-)-ketamine requires much more additional concentration effect studies for its analgesic and antidepressant effects.
was to evaluate the effects of maternal Fluoxetine treatment on offspring behaviours of relevance to neurodevelopmental and psychiatric disorders, using a rodent model of depression. Methods: Sprague-Dawley (SD; healthy model) and WistarKyoto (WKY; depression model) pregnant rats were treated with Fluoxetine (10mg/kg/day) or vehicle, from gestational day 0 to postnatal day 14 (~5 weeks in total). Once offspring reached adolescence (~5 weeks of age), locomotor activity, anxiety-like and depressive-like behaviours were assessed using the open field test (OFT), elevated plus maze (EPM) and forced swim test (FST). Results: Fluoxetine exposed offspring displayed an increase in distance travelled in the OFT, an effect that was independent of rat strain and sex. Fluoxetine exposure also caused an increase (up to 50%) in time spent in the corners of the OFT in SD male and WKY female rats compared to their respective vehicle controls. Similarly, in the EPM, maternal Fluoxetine treatment resulted in a significant increase in time spent in the closed arms in SD males and WKY males (29-52%). A similar trend was observed in females, but this did not reach significance. In the FST, maternal Fluoxetine treatment increased immobility time in exposed offspring (28%), an effect that was independent of strain or sex. Conclusion: Maternal Fluoxetine treatment resulted in significant increases in anxiety-like and depressive-like behaviours in exposed offspring, largely independent of the rat model used. However, further studies in various models of maternal depression are required to confirm these preliminary findings and establish the effects of Fluoxetine exposure on the developing brain.
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Abstract
The selective serotonin reuptake inhibitor, fluoxetine (FLX), is widely used to treat depression and anxiety disorders, but mechanisms underlying its antidepressant effect remain largely unknown. Previous studies that evaluated several molecular and/or electrophysiological features of the maturation stages of each neuron type have demonstrated that FLX treatment can reverse the established maturation of certain types of neurons in the hippocampus and frontal cortex (FC). However, this dematuration effect of FLX in the adult brain has not been assessed with regard to genome-wide gene expression patterns.
In this study, we compared gene expression patterns in the FLX-treated FC and hippocampus of adult mice with those of the corresponding brain regions of normal infant mice. The gene expression patterns of FLX-treated mice significantly resembled those of normal infant mice in the FC and, to a large extent, in the hippocampus. In addition, time-course analyses of the ages of infant mice used in the comparisons with FLX-treated mice indicated that the gene expression patterns of FLX-treated mice were most similar to those of the youngest infants examined (1-week-old hippocampus and 2-week-old FC).
